at San Francisco, California and other locations
study started
estimated completion:



The purpose of the REVERSE Post Approval Study (PAS) is to confirm the benefit observed in the REVERSE and RAFT pivotal studies in "real-world" clinical practice.

Official Title

The REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) Post Approval Study


The REVERSE PAS will estimate the 3-year survival probability of freedom from heart failure hospitalization and heart failure events in patients implanted with a Medtronic CRT-D device who meet the expanded indication criteria with a QRS duration ≤ 150 ms.


Heart Failure


You can join if…

  • Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
  • Patient has or is intended to receive or be treated with a Medtronic CRT-D who meets the expanded CRT-D indication criteria with a QRS ≤ 150ms
  • Patient within 30 days of implant

You CAN'T join if...

  • Patient who is, or will be, inaccessible for follow-up
  • Patient with exclusion criteria required by local law
  • Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results


  • San Francisco, California, 94143, United States
  • Redwood City, California, 94062, United States
  • Stanford, California, 94305, United States
  • Monterey, California, 93940, United States
  • Salinas, California, 93901, United States
  • Bakersfield, California, 93301, United States
  • Van Nuys, California, 91405, United States
  • Redding, California, 96001, United States
  • Los Angeles, California, 90048, United States
  • Downey, California, 90241, United States
  • Torrance, California, 90503, United States
  • Las Vegas, Nevada, 89169, United States
  • Henderson, Nevada, 89052, United States
  • Rancho Mirage, California, 92270, United States


accepting new patients
Start Date
Completion Date
Study Type
Last Updated
October 4, 2017